2. Search Result
Search Result
Results for "

4T1

" in MedChemExpress (MCE) Product Catalog:

160

Inhibitors & Agonists

6

Fluorescent Dye

1

Biochemical Assay Reagents

7

Peptides

10

Inhibitory Antibodies

8

Natural
Products

1

Isotope-Labeled Compounds

6

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13513
    U-104
    5+ Cited Publications

    SLC-0111

    		 Carbonic Anhydrase Cancer
    U-104 (SLC-0111) is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki values of 45.1 nM and 4.5 nM, respectively. U-104 shows a significant delay in tumor growth in mice model .
    U-104
  • HY-122844
    Ifebemtinib
    3 Publications Verification

    BI-853520; IN-10018

    		 FAK Cancer
    Ifebemtinib (BI 853520) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC50=1 nM). Ifebemtinib shows anti-proliferative activity against cancer cells. Ifebemtinib inhibits FER Kinase and FES Kinase with IC50s of 900 nM and 1040 nM, respectively .
    Ifebemtinib
  • HY-116705
    2-Deoxy-2-fluoro-L-fucose
    1 Publications Verification

    		 Glycosyltransferase Cancer
    2-Deoxy-2-fluoro-L-fucose, an L-fucose analog, is a fucosylation inhibitor. 2-Deoxy-2-fluoro-L-fucose inhibits de novo synthesis of GDP-fucose in mammalian cells. Fucosylation is a relatively well-defined biomarker for progression in many human cancers; for example, pancreatic and hepatocellular carcinoma .
    2-Deoxy-2-fluoro-L-fucose
  • HY-136552
    β-Bisabolene
    1 Publications Verification

    		 Others Cancer
    β-Bisabolene is a sesquiterpene isolated from opoponax (Commiphora guidotti). β-Bisabolene, an anti-cancer agent, can be used for the study of breast cancer .
    β-Bisabolene
  • HY-147165
    VT02956
    1 Publications Verification

    		 Ser/Thr Kinase Large Tumor Suppressor (LATS) Cancer
    VT02956 is a LATS inhibitor (IC50: 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids . VT02956 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    VT02956
  • HY-101466
    E7090

    		FGFR Cancer
    E7090 is an orally available, potent, and selective FGFR inhibitor with IC50s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4, respectively .
    E7090
  • HY-163757
    PROTAC PD-L1 degrader-1

    		PROTACs PD-1/PD-L1 Inflammation/Immunology Cancer
    PROTAC PD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with a notable PD-L1 protein degradation capability. PROTAC PD-L1 degrader-1 shows potent PD-L1 degradation in 4T1 cells with a DC50 of 0.609 μM. PROTAC PD-L1 degrader-1 can be used for the study of breast cancer. (Blue: CRBN ligand (HY-150839), Black: linker; Pink: PD-L inhibitor (HY-19745)) .
    PROTAC PD-L1 degrader-1
  • HY-162312
    LLK203

    		Deubiquitinase Apoptosis Cancer
    LLK203 is a potent USP2/USP8 dual-target inhibitor with IC50s of 0.89 μM and 0.52 μM, respectively. LLK203 leads a degradation of ERα and induces apoptosis of breast cancer MCF-7 cells. LLK203 demonstrates antitumor activities against the 4T1 tumor mice model .
    LLK203
  • HY-128972
    Purpurin 18
    2 Publications Verification

    		 Reactive Oxygen Species (ROS) Apoptosis Others
    Purpurin 18, a derivative of chlorophyll and a type of dihydroporphyrin, is used to produce photosensitizers. Purpurin 18 photodynamic therapy can induce cell apoptosis and has anti-tumor activity .
    Purpurin 18
  • HY-157913
    PKM2-IN-6

    		Pyruvate Kinase Apoptosis Cancer
    PKM2-IN-6 (compound 7d) is a potent and orally active PKM2 inhibitor with an IC50 value of 23 nM. PKM2-IN-6 induces apoptosis and cell cycle arrest at G2 phase. PKM2-IN-6 reduces the level of PKM1 and PKM2 at the mRNA level. PKM2-IN-6 shows anticancer activity and has the potential for the research of triple-negative breast cancer .
    PKM2-IN-6
  • HY-163002
    viFSP1
    4 Publications Verification

    		 Ferroptosis Cancer
    viFSP1 is a species-independent FSP1 inhibitor. viFSP1 directly inhibits FSP1 by targeting the highly conserved NAD(P)H binding pocket of FSP1. viFSP1 can induce Ferroptosis in FSP1-dependent cells. viFSP1 can be used in renal and breast cancer research .
    viFSP1
  • HY-P990145
    Anti-Mouse VISTA Antibody (13F3)

    		VISTA Inflammation/Immunology Cancer
    Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonal antibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF .
    Anti-Mouse VISTA Antibody (13F3)
  • HY-120797
    CRT0273750

    IOA-289

    		 LPL Receptor Cancer
    CRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC50 = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancer .
    CRT0273750
  • HY-P990824
    Anti-Mouse PD-1 Antibody (J43)
    1 Publications Verification

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse PD-1. Anti-Mouse PD-1 Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer .
    Anti-Mouse PD-1 Antibody (J43)
  • HY-P990789
    Anti-Mouse CTLA-4 Antibody (9H10)

    		CTLA-4 Others Inflammation/Immunology Cancer
    Anti-Mouse CTLA-4 Antibody (9H10) is a kind of syrian hamster IgG antibody inhibitor, targeting to CTLA-4. Anti-Mouse CTLA-4 Antibody (9H10) binds mouse CTLA-4 and blocks the interaction between CTLA-4 and its ligand. Anti-Mouse CTLA-4 Antibody (9H10) shows potent anti-tumor effect in various tumor models, such as breast and colon cancer .
    Anti-Mouse CTLA-4 Antibody (9H10)
  • HY-144088
    ZYF0033
    2 Publications Verification

    HPK1-IN-22

    		 MAP4K Inflammation/Immunology Cancer
    ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a +CD8 + T cells, but not T cells, PD-1 +CD8 + T cells, TIM-3 +CD8 + Infiltration of T cells and LAG3 +CD8 + T cells was reduced .
    ZYF0033
  • HY-156096
    HDAC3-IN-2

    		HDAC Histone Methyltransferase Caspase Apoptosis DNA/RNA Synthesis Cancer
    HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC50: 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC50 of 0.55 μM against 4T1 and an IC50 of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels .
    HDAC3-IN-2
  • HY-175714
    STING agonist-46

    		STING Inflammation/Immunology Cancer
    STING agonist-46 is an orally active STING agonist. STING agonist-46 activates the STING signaling pathway, promoting phosphorylation of TBK1 and IRF3, and secretion of IFN-β and IP-10. STING agonist-46 directly binds to STING and increases its thermal stability. STING agonist-46 demonstrates potent anti-tumor efficacy in B16F10, CT26, and 4T1 mouse models. STING agonist-46 can be used for cancer immunotherapy studies .
    STING agonist-46
  • HY-163343
    Enpp-1-IN-20

    		Phosphodiesterase (PDE) STING Cancer
    Enpp-1-IN-20 (Compound 31) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor, with an IC50 of 0.09 nM. Enpp-1-IN-20 has strongest inhibitory activity in the cell-based assay, with an IC50 of 8.8 nM. Enpp-1-IN-20 has significant potency in both ENPP1 inhibition and STING pathway stimulation in vitro. Enpp-1-IN-20 can be used for the research of cancer .
    Enpp-1-IN-20
  • HY-176869
    EMC-AANL-DOX

    		Drug Derivative Cancer
    EMC-AANL-DOX is a legumain-activated prodrug conjugate of Doxorubicin (DOX) (HY-15142A). EMC-AANL-DOX shows antitumor activity in mouse models of neuroblastoma (NB), breast cancer (4T1), fibrosarcoma (HT1080), and colorectal cancer liver metastases (CT26). EMC-AANL-DOX can be used for cancer research .
    EMC-AANL-DOX
  • HY-P990299
    Anti-Mouse B220 Antibody (RA3.3A1/6.1)

    		Phosphatase Inflammation/Immunology Cancer
    Anti-Mouse B220 Antibody (RA3.3A1/6.1) is a rat-derived IgM type antibody inhibitor, targeting to mouse B220. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can deplete B cells. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can be used for the researches of cancer and immunology, such as 4T1 and B16 tumor .
    Anti-Mouse B220 Antibody (RA3.3A1/6.1)
  • HY-162645
    BPR5K230

    		TAM Receptor Inflammation/Immunology Cancer
    BPR5K230 is a dual inhibitor for the receptor tyrosine kinase MER and AXL, with IC50 of 4.1 nM and 9.2 nM. BPR5K230 inhibits the proliferation of Ba/F3-MER with IC50 of 5 nM. BPR5K230 exhibits good pharmacokinetic characteristics in mice, exhibits anti-inflammatory and antitumor against 4T1, MDA-MB-231, MC38 and Hepa1?6 in mouse models .
    BPR5K230
  • HY-P99149
    Anti-Mouse TNFR2 Antibody (TR75-54.7)

    		TNF Receptor Inflammation/Immunology Cancer
    Anti-Mouse TNFR2 Antibody (TR75-54.7) is an anti-mouse TNFR2 IgG monoclonal antibody. Anti-Mouse TNFR2 Antibody (TR75-54.7) can reduce white blood cell count (WBC) and decrease the expression of some pro-inflammatory cytokines such as CCL2 and CXCL5. Anti-Mouse TNFR2 Antibody (TR75-54.7) can be used for researches on inflammation conditions and cancer such as breast cancer .
    Anti-Mouse TNFR2 Antibody (TR75-54.7)
  • HY-W348485
    WRX606

    		mTOR Cancer
    WRX606 is an orally active nonrapalog inhibitor for mTOR complex 1 (mTORC1M). WRX606 inhibits the phosphorylation of mTORC1 substrate S6 kinase 1 (S6K1) (IC50 = 10 nM) and eukaryotic translation initiation factor 4E binding protein (p-4E-BP1) (IC50 = 0.27 μM) in MCF-7 cells. WRX606 suppresses tumor growth in mice without promotion of metastasis. WRX606 can be studied in research as an antitumor agent .
    WRX606
  • HY-P990004
    Anti-Mouse TIM-3 Antibody (B8.2C12)

    		Tim3 Inflammation/Immunology Cancer
    Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 IgG1 monoclonal antibody. Anti-Mouse TIM-3 Antibody (B8.2C12) can block the binding of Tim-3 with Phosphatidylserine (PtdSer) and CEACAM1 without interfering with the binding to Galectin-9. Anti-Mouse TIM-3 Antibody (B8.2C12) can inhibit tumor growth and activate tumor infiltrating CD8 + T cells. Anti-Mouse TIM-3 Antibody (B8.2C12) can be used for studying cancer such as breast cancer and colon cancer and constructing experimental autoimmune encephalomyelitis (EAE) models .
    Anti-Mouse TIM-3 Antibody (B8.2C12)
  • HY-175478
    Enpp-1-IN-27

    		Phosphodiesterase (PDE) STING Inflammation/Immunology Cancer
    Enpp-1-IN-27 is a selective ENPP1 inhibitor with an IC50 of 14.68 nM, exhibiting approximately 410-fold selectivity against ENPP2 and 10-fold selectivity against ENPP3. Enpp-1-IN-27 stabilizes cGAMP levels and activates the STING pathway, promoting cytokine release and enhancing innate immune responses. Enpp-1-IN-27 induces ISRE activation and amplified cGAMP-mediated immune responses and shows the desired antitumor efficacy in the 4T1 and CT26 syngeneic mouse models. Enpp-1-IN-27 can used for the studies of breast cancer and colon cancer .
    Enpp-1-IN-27
  • HY-174811
    PROTAC BRD4 Degrader-33

    		PROTACs Epigenetic Reader Domain PD-1/PD-L1 Inflammation/Immunology Cancer
    PROTAC BRD4 Degrader-33 is an enzyme activated clickable BRD4 PROTAC degrader with favorable tumor microenvironment-response. PROTAC BRD4 Degrader-33 has superior tumor tissue penetration capabilities and efficiently inhibits PD-L1 protein expression. PROTAC BRD4 Degrader-33 shows potent anti-tumoral immunomodulation activity in 4T1 tumor-bearing mice model . Pink: BRD4 ligand (HY-174812); Blue: CRBN ligase ligand (HY-10984); Black: linker
    PROTAC BRD4 Degrader-33
  • HY-178914
    Copper ionophore I

    		Cuproptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism Cancer
    Copper ionophore I is an efficient copper ion carrier. Copper ionophore I can regulate various intracellular copper levels to induce cuproptosis, such as 4T1 (IC50 = 0.45 μM) and MDA-MB-231(IC50 = 1.21 μM) cells. Copper ionophore I can induce an increase in ROS and cause mitochondrial dysfunction. Copper ionophore I can reduce the expression of FDX1, DLAT, and LIAS proteins. Copper ionophore I can activate immune related pathways and promote T cell infiltration. Copper ionophore I can be used for cancer research .
    Copper ionophore I
  • HY-P990208
    Anti-Mouse IL-9 Antibody (9C1)

    		Interleukin Related NF-κB Parasite Infection Inflammation/Immunology Cancer
    Anti-Mouse IL-9 Antibody (9C1) is an anti-mouse IL-9 IgG2a monoclonal antibody. Anti-Mouse IL-9 Antibody (9C1) can reduce the activation of NF-κB signaling pathway and decrease the infiltration of inflammatory cells. Anti-Mouse IL-9 Antibody (9C1) effectively reduces Th9 cell-mediated allergic reactions and anti-tumor effects. Anti-Mouse IL-9 Antibody (9C1) can be used for researches on inflammation, infection conditions and cancer such as parasitic infections, allergic reactions, breast cancer and osteosarcoma .
    Anti-Mouse IL-9 Antibody (9C1)
  • HY-P990279
    Anti-Mouse CD276/B7-H3 Antibody (MJ18)

    		CD276/B7-H3 Apoptosis STAT Inflammation/Immunology Cancer
    Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .
    Anti-Mouse CD276/B7-H3 Antibody (MJ18)
  • HY-151904
    AXL-IN-13

    		TAM Receptor FLT3 PDGFR Cancer
    AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion .
    AXL-IN-13
  • HY-175874
    Tubulin-IN-55

    		Microtubule/Tubulin PI3K Akt Apoptosis Cancer
    Tubulin-IN-55 is a tubulin inhibitor. Tubulin-IN-55 disrupts the PI3K/Akt signaling pathway in cancer cells. Tubulin-IN-55 exerts broad-spectrum anti-proliferative activity against multiple tumor cells (HeLa, HCT116, 4T1, A549, H1299, MDA-MB231). Tubulin-IN-55 induces G2/M phase arrest and apoptosis, and inhibits tumor cell migration/invasion in cancer cells. Tubulin-IN-55 demonstrates potent antitumor efficacy in orthotopic autologous transplantation mice. Tubulin-IN-55 can be used for the study of cancer .
    Tubulin-IN-55
  • HY-150158
    TMX-201

    		Toll-like Receptor (TLR) Cancer
    TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research .
    TMX-201
  • HY-163709
    PROTAC FAK degrader 2

    		PROTACs FAK Cancer
    PROTAC FAK degrader 2 (Compound F2) is a PROTAC degrader for focal adhesion kinase (FAK), with DC50 of 27.72 and 60.1 nM, for total FAK and phosphorylated p-FAK. PROTAC FAK degrader 2 inhibits cell viability of cancer cells 4T1, MDA-MB-231, MDA-MB-468 and MDA-MB-435, with IC50s of 0.73-5.84 μM. PROTAC FAK degrader 2 reverses the multidrug resistance (MDR) through inhibition of AKT and ERK signaling pathway. PROTAC FAK degrader 2 exhibits antitumor efficacy in HCT/8 xenograft mouse model. (Pink: ligand for target protein Ifebemtinib (HY-122844); Black: linker (HY-Y0681); Blue: ligand for E3 ligase Thalidomide (HY-14658))
    PROTAC FAK degrader 2
  • HY-175846
    TQFL13

    		Drug Derivative Apoptosis Cancer
    TQFL13 is derivative of Thymoquinone (TQ) (HY-D0803) with potent anti-breast cancer activity. TQFL13 exhibits higher cytotoxicity against breast cancer cells (BT549, MDA-MB-231, 4T1). TQFL13 increases apoptosis and blocks the cell cycle at S and G2/G1 phases in breast cancer cells. TQFL13 shows dose-dependent anti-tumor efficacy in mouse breast cancer allograft model. TQFL13 can be used for the study of breast cancer .
    TQFL13
  • HY-170453
    iHAC

    		Epigenetic Reader Domain Cancer
    iHAC is an inhibitor HSP90-anchoring chimera, that covalently binds BRD4 ligand (+)-JQ-1 to HSP90, and inhibits the proliferation of cancer cells. iHAC activates the anti-tumor immune response, inhibits the recurrence and metastasis of 4T1 breast cancer in mouse models .
    iHAC
  • HY-169392
    D5B

    		PD-1/PD-L1 Cancer
    D5B is a potent and selective PD-L1 inhibitor. D5B has been modified by DBCO. The EC50 of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity .
    D5B
  • HY-124439
    Setomimycin

    		Antibiotic Bacterial SARS-CoV Infection Cancer
    Setomimycin is a potent antibiotic. Setomimycin inhibits the SARS-CoV-2 Mpro enzyme with an IC50 value of 12.02 µM. Setomimycin shows anti-inflammatory and antioxidant properties. Setomimycin shows antiproliferative and antitumor activity .
    Setomimycin
  • HY-172934
    FGT-4

    		Toll-like Receptor (TLR) NO Synthase PROTACs Inflammation/Immunology Cancer
    FGT-4 is a folate receptor β (FR-β) targeting chimeric molecule. FGT-4 is a TLR7 agonist. FGT-4 facilitates the secretion of iNOS and proinflammatory cytokine IL-6 associated with M1 macrophages and enhances the proliferation of cytotoxic CD8 + T cells. FGT-4 has anti-tumor activity in the 4T1 breast cancer mouse model. FGT-4 can be used for the study of cancer immunity. (Pink: target protein TLR7/8 agonist 1 ligand (HY-103698); black: linker (HY-172936); blue: FR-β ligand (HY-172935)) .
    FGT-4
  • HY-175857
    HDAC-IN-92

    		HDAC Apoptosis Cancer
    HDAC-IN-92 is a pan-HDAC inhibitor with an IC50 of 12.58 µM in A2780 cells. HDAC-IN-92 demonstrates broad-spectrum, notable cytotoxic activity against a range of human cancer cell lines, including ovarian, liver, and breast carcinomas. HDAC-IN-92 causes apoptosis and demonstrates a notable decrease in tumor cell colony formation. HDAC-IN-92 inhibits the formation of blood vessels in the chick chorioallantoic membrane (CAM). HDAC-IN-92 exhibits anti-tumor effect in a 4T1 tumor-bearing mouse model. HDAC-IN-92 can be used for research targeting solid tumor .
    HDAC-IN-92
  • HY-174403
    c-MYC/BCL2 ligand 1 iodide

    		Bcl-2 Family c-Myc Apoptosis Caspase Cancer
    c-MYC/BCL2 ligand 1 iodide is a dual-targeting c-MYC/Bcl-2 G4 ligand with Kd values of 0.90 μM (c-MYC G4) and 0.56 μM (Bcl-2 G4). c-MYC/BCL2 ligand 1 iodide inhibits c-MYC and Bcl-2 gene transcription by binding to G4-forming sequences and downregulates their protein expression. c-MYC/BCL2 ligand 1 iodide inhibits suppresses migration, induces caspase-dependent apoptosis, and triggers cell cycle G1 arrest in MCF-7 cells. c-MYC/BCL2 ligand 1 iodide significantly suppresses tumor growth in a 4T1 syngeneic model with no observable toxicity. c-MYC/BCL2 ligand 1 iodide can be used for the research of breast cancer.
    c-MYC/BCL2 ligand 1 iodide
  • HY-159771
    FAP6-19

    		FAP Cancer
    FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
    FAP6-19
  • HY-156296
    CDK9-Cyclin T1 PPI-IN-1

    		CDK Apoptosis Cancer
    CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC50: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model .
    CDK9-Cyclin T1 PPI-IN-1
  • HY-175227
    STAT3/NF-κB-IN-1

    		STAT NF-κB Apoptosis Caspase Bcl-2 Family Cancer
    STAT3/NF-κB-IN-1 is a potentSTAT3 and NF-κB inhibitor with IC50s of 5.86 (STAT3) and 4.22 μM (NF-κB) in 4T1 cells. STAT3/NF-κB-IN-1 is able to induce apoptosis via its upregulation on key apoptotic regulators; caspases-3/9, Bax and downregulation of Bcl-2. STAT3/NF-κB-IN-1 exerts considerable anticancer activity against breast cancer cell lines and reduces tumor volume in vivo. STAT3/NF-κB-IN-1 can be used for the study of breast cancer .
    STAT3/NF-κB-IN-1
  • HY-155745
    Antitumor agent-115

    		Apoptosis Cancer
    Antitumor agent-115 (SS-12) is an effective anti-tumor compound with an IC50 value of 0.34 μM-24.14 μM for cell line 4T1. Antitumor agent-115 can block the cell cycle of mouse breast cancer cell line 4T1, reduce the mitochondrial membrane potential, and induce apoptosis, and the IC50 value is 8-25 μmol/L for cell viability. Antitumor agent-115 can be used for breast cancer research .
    Antitumor agent-115
  • HY-162958
    Photosensitizer-6

    		Apoptosis TrxR Cancer
    Photosensitizer-6 (Compound 4) is a gold (I) complex and exhibits inhibitory activity against TrxR. Photosensitizer-6 induces apoptosis in 4T1 cell, targets and eradicates tumors through chemo-phototherapy and immunogenic cell death under light exposure. Photosensitizer-6 can be used for tumor imaging .
    Photosensitizer-6
  • HY-173060
    ERK1/2 inhibitor 13

    		ERK Apoptosis Autophagy Cancer
    ERK1/2 inhibitor 13 (Compound 21y) is the orally active inhibitor for ERK that inhibits ERK1 and ERK2 with IC50 of 91.71 nM and 97.87 nM. ERK1/2 inhibitor 13 inhibits the proliferation of MCF-7, 4T1, MDA-MB-468, and HCC1970 (IC50 of 0.67, 2.76, 2.15 and 1.68 μM), inhibits the cancer cell migration, induces apoptosis and autophagy in MCF-7. ERK1/2 inhibitor 13 exhibits antitumor and anti-metastatic effect in 4T1 xenograft mouse model .
    ERK1/2 inhibitor 13
  • HY-170989
    BRD4 degrader-5

    		AUTACs Epigenetic Reader Domain Autophagy Cancer
    BRD4 degrader-5 (Compound 23) is a hydrophobic tag (HyTag)-based protein degrader for BRD4 (DC50 = 24.7 μM) through ER stress and autophagy-lysosome pathway. BRD4 degrader-5 inhibits the proliferation of cancer cell 4T1 with an IC50 of 20.6 μM .
    BRD4 degrader-5
  • HY-D2620
    CAR-2

    		Photosensitizer Reactive Oxygen Species (ROS) Ferroptosis Cancer
    CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC50 of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models .
    CAR-2
  • HY-175981
    Paclitaxel-bromothiophene

    		Drug Derivative Cancer
    Paclitaxel-bromothiophene is a semisynthetic taxane analogue of Paclitaxel (HY-B0015). Paclitaxel-bromothiophene exhibits potent antiproliferative activity against 4-T1 breast cancer cells, with an IC50 value of 15.18 nM. Paclitaxel-bromothiophene shows high binding affinity to C5aR1 (Kd = 19.4 μM). Paclitaxel-bromothiophene demonstrates excellent anti-tumor efficacy in 4-T1 breast cancer-bearing mice. Paclitaxel-bromothiophene can be used for the study of breast cancer .
    Paclitaxel-bromothiophene

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: